Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 34 | 2017 | 849 | 3.130 |
Why?
|
Glomerulonephritis | 7 | 2018 | 75 | 2.510 |
Why?
|
Kidney Glomerulus | 8 | 2018 | 123 | 2.140 |
Why?
|
Skin Neoplasms | 12 | 2018 | 546 | 1.930 |
Why?
|
Kidney | 19 | 2017 | 1241 | 1.670 |
Why?
|
Biopsy | 24 | 2021 | 1163 | 1.450 |
Why?
|
Glomerulosclerosis, Focal Segmental | 8 | 2012 | 38 | 1.410 |
Why?
|
Graft Rejection | 17 | 2012 | 1065 | 1.380 |
Why?
|
Capillaries | 8 | 2014 | 91 | 1.280 |
Why?
|
Acute Kidney Injury | 7 | 2018 | 295 | 1.190 |
Why?
|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2015 | 7 | 1.040 |
Why?
|
Complement C4b | 4 | 2012 | 35 | 0.920 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 4 | 2015 | 21 | 0.910 |
Why?
|
Glomerulonephritis, Membranous | 3 | 2014 | 24 | 0.900 |
Why?
|
Dysplastic Nevus Syndrome | 3 | 2018 | 9 | 0.880 |
Why?
|
Kidney Diseases | 10 | 2017 | 418 | 0.860 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 199 | 0.830 |
Why?
|
Dermal Fillers | 1 | 2021 | 3 | 0.790 |
Why?
|
Peptide Fragments | 4 | 2012 | 460 | 0.790 |
Why?
|
Viscosupplements | 1 | 2021 | 5 | 0.790 |
Why?
|
Hyaluronic Acid | 1 | 2021 | 49 | 0.770 |
Why?
|
Polyomavirus Infections | 7 | 2017 | 28 | 0.750 |
Why?
|
Photomicrography | 1 | 2019 | 7 | 0.730 |
Why?
|
Nephrotic Syndrome | 3 | 2018 | 33 | 0.730 |
Why?
|
Nevus, Pigmented | 3 | 2018 | 49 | 0.730 |
Why?
|
Dermatology | 1 | 2019 | 35 | 0.700 |
Why?
|
Immunosuppressive Agents | 13 | 2015 | 977 | 0.690 |
Why?
|
Transplantation, Homologous | 14 | 2014 | 996 | 0.680 |
Why?
|
Tumor Virus Infections | 6 | 2017 | 81 | 0.670 |
Why?
|
Margins of Excision | 1 | 2018 | 39 | 0.650 |
Why?
|
Graft Survival | 8 | 2010 | 884 | 0.640 |
Why?
|
Kidney Tubules | 3 | 2014 | 94 | 0.630 |
Why?
|
Skin Diseases | 1 | 2019 | 166 | 0.630 |
Why?
|
Female | 54 | 2021 | 44532 | 0.620 |
Why?
|
Nephritis, Interstitial | 6 | 2005 | 47 | 0.610 |
Why?
|
Renal Dialysis | 2 | 2018 | 355 | 0.610 |
Why?
|
Male | 55 | 2021 | 40965 | 0.590 |
Why?
|
Amyloidosis | 1 | 2018 | 115 | 0.580 |
Why?
|
Adult | 39 | 2021 | 25648 | 0.570 |
Why?
|
Polyomavirus | 2 | 2006 | 16 | 0.570 |
Why?
|
Humans | 77 | 2021 | 86643 | 0.560 |
Why?
|
Middle Aged | 38 | 2021 | 25028 | 0.550 |
Why?
|
Streptococcal Infections | 1 | 2015 | 57 | 0.530 |
Why?
|
Blood Platelets | 2 | 2008 | 149 | 0.530 |
Why?
|
Immunohistochemistry | 13 | 2018 | 1753 | 0.520 |
Why?
|
Muscle Neoplasms | 2 | 2013 | 18 | 0.510 |
Why?
|
Chemotaxis | 1 | 2014 | 72 | 0.500 |
Why?
|
Hemolysis | 1 | 2014 | 61 | 0.500 |
Why?
|
Lupus Nephritis | 3 | 2012 | 78 | 0.490 |
Why?
|
Hemoglobins | 1 | 2014 | 179 | 0.480 |
Why?
|
BK Virus | 6 | 2017 | 23 | 0.480 |
Why?
|
Terminology as Topic | 1 | 2015 | 217 | 0.480 |
Why?
|
Retrospective Studies | 15 | 2021 | 8489 | 0.480 |
Why?
|
Nevus, Blue | 1 | 2013 | 5 | 0.470 |
Why?
|
Melanocytes | 2 | 2013 | 56 | 0.470 |
Why?
|
Hamartoma | 1 | 2013 | 31 | 0.460 |
Why?
|
Fox-Fordyce Disease | 1 | 2012 | 2 | 0.450 |
Why?
|
Staphylococcal Infections | 1 | 2015 | 255 | 0.440 |
Why?
|
Aged | 22 | 2021 | 18415 | 0.440 |
Why?
|
Melanoma, Amelanotic | 1 | 2011 | 1 | 0.420 |
Why?
|
Chromoblastomycosis | 1 | 2011 | 2 | 0.420 |
Why?
|
Internship and Residency | 2 | 2019 | 1004 | 0.410 |
Why?
|
Macrophages | 2 | 2014 | 554 | 0.410 |
Why?
|
Plasma Cells | 5 | 2012 | 80 | 0.400 |
Why?
|
Respiratory Paralysis | 1 | 2010 | 8 | 0.390 |
Why?
|
Sickle Cell Trait | 1 | 2011 | 21 | 0.390 |
Why?
|
Thrombotic Microangiopathies | 1 | 2010 | 21 | 0.380 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 2012 | 206 | 0.380 |
Why?
|
Integrin beta3 | 2 | 2008 | 30 | 0.380 |
Why?
|
Renal Artery | 1 | 2011 | 64 | 0.370 |
Why?
|
Spinal Cord Injuries | 1 | 2010 | 54 | 0.370 |
Why?
|
Vascular Diseases | 1 | 2011 | 121 | 0.360 |
Why?
|
Kidney Failure, Chronic | 2 | 2014 | 509 | 0.360 |
Why?
|
Glomerular Mesangium | 2 | 2018 | 23 | 0.360 |
Why?
|
Facial Dermatoses | 4 | 2011 | 13 | 0.350 |
Why?
|
Glomerulonephritis, Membranoproliferative | 1 | 2008 | 14 | 0.330 |
Why?
|
Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.320 |
Why?
|
Skin | 4 | 2021 | 554 | 0.320 |
Why?
|
Respiration, Artificial | 1 | 2010 | 334 | 0.310 |
Why?
|
Calcineurin Inhibitors | 1 | 2008 | 54 | 0.310 |
Why?
|
Granuloma | 2 | 2012 | 65 | 0.300 |
Why?
|
Time Factors | 9 | 2018 | 5210 | 0.300 |
Why?
|
Antigens, Viral, Tumor | 1 | 2006 | 15 | 0.290 |
Why?
|
Aged, 80 and over | 9 | 2021 | 6509 | 0.290 |
Why?
|
Microscopy | 2 | 2019 | 87 | 0.280 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1197 | 0.280 |
Why?
|
Scalp Dermatoses | 3 | 2011 | 10 | 0.270 |
Why?
|
Biomarkers | 5 | 2015 | 1718 | 0.270 |
Why?
|
Adolescent | 12 | 2016 | 8981 | 0.270 |
Why?
|
Proteinuria | 3 | 2004 | 107 | 0.260 |
Why?
|
Child | 11 | 2016 | 6927 | 0.260 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 639 | 0.250 |
Why?
|
Biomarkers, Tumor | 2 | 2011 | 1464 | 0.250 |
Why?
|
Fabry Disease | 1 | 2004 | 6 | 0.240 |
Why?
|
Diagnosis, Differential | 9 | 2013 | 1565 | 0.240 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 1052 | 0.240 |
Why?
|
Cytomegalovirus Infections | 1 | 2004 | 144 | 0.240 |
Why?
|
Creatinine | 7 | 2014 | 338 | 0.230 |
Why?
|
Eosinophils | 2 | 2021 | 194 | 0.230 |
Why?
|
HIV Infections | 1 | 2012 | 772 | 0.230 |
Why?
|
Child, Preschool | 8 | 2016 | 3612 | 0.230 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 1686 | 0.220 |
Why?
|
Glomerulonephritis, IGA | 2 | 2000 | 10 | 0.220 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 469 | 0.220 |
Why?
|
Cell Nucleus | 2 | 2011 | 579 | 0.210 |
Why?
|
Lymphoproliferative Disorders | 2 | 2011 | 107 | 0.210 |
Why?
|
Sex Factors | 2 | 2018 | 1054 | 0.210 |
Why?
|
Disease Progression | 6 | 2018 | 1531 | 0.210 |
Why?
|
Young Adult | 6 | 2018 | 5976 | 0.210 |
Why?
|
Hypersensitivity, Delayed | 1 | 2021 | 25 | 0.210 |
Why?
|
Isoxazoles | 3 | 2006 | 77 | 0.200 |
Why?
|
Eosinophilic Granuloma | 1 | 2021 | 10 | 0.200 |
Why?
|
Histiocytes | 1 | 2021 | 22 | 0.200 |
Why?
|
Jaw Diseases | 1 | 2000 | 7 | 0.200 |
Why?
|
Acute Disease | 4 | 2010 | 826 | 0.200 |
Why?
|
Facial Pain | 1 | 2000 | 10 | 0.200 |
Why?
|
Chicago | 4 | 2015 | 1379 | 0.190 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 92 | 0.190 |
Why?
|
Viremia | 2 | 2017 | 54 | 0.190 |
Why?
|
Immunoglobulin A | 1 | 2000 | 80 | 0.190 |
Why?
|
Biopsy, Needle | 3 | 2018 | 235 | 0.190 |
Why?
|
Risk Assessment | 4 | 2018 | 2261 | 0.180 |
Why?
|
Giant Cells | 1 | 1999 | 19 | 0.180 |
Why?
|
Follow-Up Studies | 4 | 2018 | 3640 | 0.180 |
Why?
|
Endothelium, Vascular | 3 | 2012 | 435 | 0.180 |
Why?
|
Postoperative Complications | 5 | 2006 | 2207 | 0.180 |
Why?
|
Carcinoma, Basal Cell | 1 | 1999 | 54 | 0.170 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2016 | 12 | 0.170 |
Why?
|
Necrosis | 2 | 2014 | 204 | 0.170 |
Why?
|
Renal Insufficiency | 2 | 2012 | 114 | 0.170 |
Why?
|
Cyclophosphamide | 2 | 2015 | 299 | 0.170 |
Why?
|
Stromal Cells | 1 | 1999 | 143 | 0.170 |
Why?
|
Nephrectomy | 3 | 2011 | 294 | 0.170 |
Why?
|
False Negative Reactions | 1 | 2018 | 63 | 0.160 |
Why?
|
Serum Amyloid A Protein | 1 | 2018 | 25 | 0.160 |
Why?
|
Inflammation | 3 | 2021 | 920 | 0.160 |
Why?
|
Dermatitis | 2 | 2021 | 32 | 0.160 |
Why?
|
Immunocompromised Host | 2 | 2011 | 140 | 0.160 |
Why?
|
Antiviral Agents | 4 | 2008 | 510 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 2 | 2015 | 263 | 0.160 |
Why?
|
Educational Measurement | 1 | 2019 | 225 | 0.160 |
Why?
|
Bone Marrow Transplantation | 4 | 2000 | 286 | 0.150 |
Why?
|
Tacrolimus | 3 | 2012 | 373 | 0.150 |
Why?
|
DNA Fragmentation | 1 | 1997 | 63 | 0.150 |
Why?
|
Transplantation, Heterologous | 4 | 2000 | 363 | 0.150 |
Why?
|
Case-Control Studies | 4 | 2016 | 1805 | 0.150 |
Why?
|
Survival Rate | 2 | 2011 | 1863 | 0.150 |
Why?
|
Chi-Square Distribution | 3 | 2010 | 364 | 0.140 |
Why?
|
Learning | 1 | 2019 | 280 | 0.140 |
Why?
|
Antigens, CD | 3 | 2014 | 458 | 0.140 |
Why?
|
DNA, Viral | 1 | 2017 | 265 | 0.140 |
Why?
|
Skin Diseases, Genetic | 1 | 2016 | 2 | 0.140 |
Why?
|
Longitudinal Studies | 1 | 2019 | 1019 | 0.140 |
Why?
|
Contracture | 1 | 2016 | 18 | 0.140 |
Why?
|
Kidney Medulla | 2 | 2014 | 80 | 0.140 |
Why?
|
Receptors, Cell Surface | 2 | 2014 | 286 | 0.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 22 | 0.140 |
Why?
|
Glomerular Filtration Rate | 2 | 2015 | 384 | 0.140 |
Why?
|
Clinical Decision-Making | 1 | 2018 | 257 | 0.140 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 100 | 0.140 |
Why?
|
Macrophage Activation | 2 | 2014 | 46 | 0.140 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1997 | 315 | 0.140 |
Why?
|
Glucocorticoids | 3 | 2012 | 352 | 0.130 |
Why?
|
Epithelial Cells | 1 | 1999 | 669 | 0.130 |
Why?
|
Curriculum | 1 | 2019 | 539 | 0.130 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2014 | 32 | 0.130 |
Why?
|
RNA-Binding Proteins | 1 | 1997 | 246 | 0.130 |
Why?
|
Neutrophil Infiltration | 1 | 2014 | 28 | 0.130 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2014 | 134 | 0.130 |
Why?
|
Treatment Outcome | 3 | 2018 | 7993 | 0.130 |
Why?
|
Rituximab | 1 | 2015 | 116 | 0.120 |
Why?
|
Risk Factors | 3 | 2016 | 5417 | 0.120 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 1673 | 0.120 |
Why?
|
Elementary Particles | 1 | 2014 | 11 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2016 | 2705 | 0.120 |
Why?
|
Quantum Theory | 1 | 2014 | 28 | 0.120 |
Why?
|
Vasculitis | 3 | 2021 | 39 | 0.120 |
Why?
|
Infant | 5 | 2016 | 3046 | 0.120 |
Why?
|
Clinical Competence | 1 | 2019 | 751 | 0.120 |
Why?
|
Prospective Studies | 2 | 2019 | 4213 | 0.120 |
Why?
|
Thrombosis | 2 | 2014 | 296 | 0.120 |
Why?
|
Erythrocytes | 1 | 2014 | 255 | 0.120 |
Why?
|
Hepatorenal Syndrome | 1 | 2013 | 8 | 0.110 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2013 | 23 | 0.110 |
Why?
|
Melanoma | 2 | 2011 | 459 | 0.110 |
Why?
|
Vulvar Diseases | 1 | 2012 | 8 | 0.110 |
Why?
|
Fluocinolone Acetonide | 1 | 2012 | 8 | 0.110 |
Why?
|
Bile | 1 | 2013 | 57 | 0.110 |
Why?
|
Cyclosporine | 5 | 2008 | 234 | 0.110 |
Why?
|
Bilirubin | 1 | 2013 | 125 | 0.110 |
Why?
|
Nipples | 1 | 2012 | 37 | 0.110 |
Why?
|
Kidney Neoplasms | 2 | 2009 | 621 | 0.110 |
Why?
|
Anemia, Sickle Cell | 1 | 2014 | 131 | 0.110 |
Why?
|
Axilla | 1 | 2012 | 99 | 0.110 |
Why?
|
Apoptosis | 3 | 2000 | 1683 | 0.110 |
Why?
|
Phaeohyphomycosis | 1 | 2011 | 1 | 0.100 |
Why?
|
Lichenoid Eruptions | 1 | 2011 | 3 | 0.100 |
Why?
|
Purpura | 1 | 2011 | 8 | 0.100 |
Why?
|
Costa Rica | 1 | 2011 | 15 | 0.100 |
Why?
|
Voriconazole | 1 | 2011 | 17 | 0.100 |
Why?
|
Photosensitivity Disorders | 1 | 2011 | 15 | 0.100 |
Why?
|
Vitiligo | 1 | 2011 | 15 | 0.100 |
Why?
|
Itraconazole | 1 | 2011 | 11 | 0.100 |
Why?
|
Melanins | 1 | 2011 | 23 | 0.100 |
Why?
|
Amphotericin B | 1 | 2011 | 34 | 0.100 |
Why?
|
Soil Microbiology | 1 | 2011 | 21 | 0.100 |
Why?
|
Erythema | 1 | 2011 | 27 | 0.100 |
Why?
|
Immunoenzyme Techniques | 2 | 2003 | 303 | 0.100 |
Why?
|
Microcirculation | 1 | 2012 | 106 | 0.100 |
Why?
|
Proteins | 1 | 1997 | 777 | 0.100 |
Why?
|
Tissue Donors | 1 | 2014 | 463 | 0.100 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2011 | 78 | 0.100 |
Why?
|
Leg | 1 | 2011 | 137 | 0.100 |
Why?
|
Mitosis | 1 | 2011 | 153 | 0.100 |
Why?
|
Antibodies, Antinuclear | 2 | 2012 | 83 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 151 | 0.100 |
Why?
|
Models, Theoretical | 1 | 2014 | 482 | 0.100 |
Why?
|
Triazoles | 1 | 2011 | 96 | 0.100 |
Why?
|
Observer Variation | 1 | 2012 | 602 | 0.100 |
Why?
|
Kidney Tubules, Proximal | 2 | 2013 | 61 | 0.100 |
Why?
|
Antifungal Agents | 1 | 2011 | 117 | 0.100 |
Why?
|
England | 1 | 2010 | 41 | 0.100 |
Why?
|
B-Lymphocyte Subsets | 1 | 2010 | 40 | 0.100 |
Why?
|
Membrane Proteins | 1 | 1997 | 1196 | 0.090 |
Why?
|
Arterioles | 2 | 2008 | 22 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 350 | 0.090 |
Why?
|
Pneumonia | 1 | 2011 | 179 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2438 | 0.090 |
Why?
|
Keratosis, Seborrheic | 1 | 2009 | 6 | 0.090 |
Why?
|
Electron Probe Microanalysis | 1 | 2009 | 8 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 1076 | 0.090 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2008 | 5 | 0.080 |
Why?
|
Lichen Planus | 1 | 2008 | 10 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2011 | 1204 | 0.080 |
Why?
|
Pyrimidines | 1 | 2011 | 370 | 0.080 |
Why?
|
Odds Ratio | 1 | 2010 | 678 | 0.080 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2009 | 97 | 0.080 |
Why?
|
Exercise | 1 | 2011 | 315 | 0.080 |
Why?
|
Platelet Activation | 1 | 2008 | 13 | 0.080 |
Why?
|
Phenotype | 1 | 2014 | 2378 | 0.080 |
Why?
|
Platelet Aggregation | 1 | 2008 | 44 | 0.080 |
Why?
|
Antigen-Antibody Complex | 1 | 2008 | 87 | 0.080 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2012 | 71 | 0.080 |
Why?
|
RNA, Viral | 3 | 2012 | 327 | 0.080 |
Why?
|
Thymus Gland | 3 | 1997 | 195 | 0.080 |
Why?
|
Pathology, Surgical | 1 | 2007 | 12 | 0.080 |
Why?
|
Prognosis | 4 | 2016 | 3679 | 0.080 |
Why?
|
Immune Tolerance | 3 | 1999 | 337 | 0.080 |
Why?
|
Hidradenitis | 1 | 2006 | 2 | 0.070 |
Why?
|
Incidental Findings | 1 | 2007 | 95 | 0.070 |
Why?
|
Cellulitis | 1 | 2006 | 19 | 0.070 |
Why?
|
Bowman Capsule | 1 | 2006 | 6 | 0.070 |
Why?
|
Comorbidity | 1 | 2010 | 943 | 0.070 |
Why?
|
Hepatitis C | 3 | 2012 | 208 | 0.070 |
Why?
|
Neprilysin | 1 | 2006 | 42 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2016 | 316 | 0.070 |
Why?
|
Mucin-1 | 1 | 2006 | 44 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2007 | 160 | 0.070 |
Why?
|
Actins | 2 | 1999 | 451 | 0.070 |
Why?
|
Cytarabine | 1 | 2006 | 218 | 0.070 |
Why?
|
Histocompatibility Antigens Class I | 2 | 1997 | 203 | 0.070 |
Why?
|
Nephrocalcinosis | 1 | 2005 | 9 | 0.070 |
Why?
|
Psoriasis | 1 | 2008 | 240 | 0.070 |
Why?
|
Recurrence | 1 | 2008 | 1139 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2011 | 1313 | 0.070 |
Why?
|
Kidney Pelvis | 1 | 2005 | 50 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 189 | 0.060 |
Why?
|
Fibrosis | 1 | 2005 | 203 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2010 | 2379 | 0.060 |
Why?
|
alpha-Galactosidase | 1 | 2004 | 5 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2007 | 369 | 0.060 |
Why?
|
Age Factors | 2 | 2016 | 1851 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2009 | 705 | 0.060 |
Why?
|
Nephritis | 1 | 2003 | 20 | 0.060 |
Why?
|
Alanine Transaminase | 2 | 2013 | 73 | 0.060 |
Why?
|
Point Mutation | 1 | 2004 | 246 | 0.060 |
Why?
|
Organophosphonates | 1 | 2003 | 50 | 0.060 |
Why?
|
Antigens, CD34 | 1 | 2003 | 158 | 0.060 |
Why?
|
Swine | 6 | 2000 | 555 | 0.050 |
Why?
|
Organophosphorus Compounds | 1 | 2003 | 55 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2006 | 239 | 0.050 |
Why?
|
Rats | 3 | 2005 | 3990 | 0.050 |
Why?
|
Neoplasm Staging | 4 | 2016 | 1939 | 0.050 |
Why?
|
Antigens, CD20 | 2 | 2012 | 36 | 0.050 |
Why?
|
Organ Transplantation | 1 | 2006 | 265 | 0.050 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 486 | 0.050 |
Why?
|
Cytosine | 1 | 2003 | 127 | 0.050 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2021 | 10 | 0.050 |
Why?
|
Kidney Calculi | 1 | 2005 | 339 | 0.050 |
Why?
|
Pemphigoid, Bullous | 1 | 2021 | 12 | 0.050 |
Why?
|
Muscle, Smooth | 2 | 2000 | 354 | 0.050 |
Why?
|
Periapical Diseases | 1 | 2000 | 2 | 0.050 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2000 | 10 | 0.050 |
Why?
|
Periodontal Diseases | 1 | 2000 | 9 | 0.050 |
Why?
|
Osteomyelitis | 1 | 2000 | 54 | 0.050 |
Why?
|
Cell Count | 1 | 2001 | 195 | 0.050 |
Why?
|
Cell Movement | 2 | 2010 | 758 | 0.050 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2001 | 50 | 0.050 |
Why?
|
Ligaments | 1 | 2000 | 32 | 0.050 |
Why?
|
Abdominal Neoplasms | 1 | 2000 | 39 | 0.050 |
Why?
|
Genes, Immunoglobulin | 1 | 2001 | 111 | 0.050 |
Why?
|
In Situ Hybridization | 1 | 2001 | 307 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2006 | 763 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2001 | 114 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2007 | 878 | 0.050 |
Why?
|
Cadaver | 1 | 2000 | 185 | 0.050 |
Why?
|
Gene Rearrangement | 1 | 2001 | 170 | 0.050 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2000 | 62 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2003 | 332 | 0.050 |
Why?
|
Keratins | 1 | 1999 | 63 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2003 | 1991 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2000 | 180 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2017 | 927 | 0.040 |
Why?
|
Swine, Miniature | 4 | 2000 | 51 | 0.040 |
Why?
|
Transplantation Tolerance | 1 | 2000 | 130 | 0.040 |
Why?
|
Macaca fascicularis | 4 | 2000 | 108 | 0.040 |
Why?
|
Flow Cytometry | 2 | 1997 | 679 | 0.040 |
Why?
|
Postoperative Period | 1 | 1999 | 303 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2005 | 2232 | 0.040 |
Why?
|
Antibodies | 2 | 1997 | 350 | 0.040 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 1997 | 6 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 1920 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 1998 | 503 | 0.040 |
Why?
|
T-Cell Intracellular Antigen-1 | 1 | 1997 | 6 | 0.040 |
Why?
|
Plasma | 1 | 2017 | 50 | 0.040 |
Why?
|
Poly(A)-Binding Proteins | 1 | 1997 | 9 | 0.040 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2017 | 47 | 0.040 |
Why?
|
Antigens, Differentiation | 1 | 1997 | 141 | 0.040 |
Why?
|
Living Donors | 1 | 2000 | 339 | 0.040 |
Why?
|
Thymectomy | 1 | 1997 | 31 | 0.040 |
Why?
|
Phenanthridines | 1 | 1996 | 24 | 0.040 |
Why?
|
Immunoconjugates | 1 | 1997 | 106 | 0.040 |
Why?
|
Transplantation Immunology | 1 | 1997 | 84 | 0.040 |
Why?
|
Incidence | 2 | 1998 | 1577 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2003 | 1204 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1997 | 165 | 0.040 |
Why?
|
Platelet Activating Factor | 1 | 1996 | 53 | 0.040 |
Why?
|
Renal Circulation | 1 | 1996 | 61 | 0.040 |
Why?
|
Microfilament Proteins | 1 | 1998 | 208 | 0.040 |
Why?
|
CD3 Complex | 2 | 2012 | 135 | 0.040 |
Why?
|
Triazines | 1 | 1996 | 53 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 1997 | 196 | 0.030 |
Why?
|
Crotonates | 2 | 2006 | 11 | 0.030 |
Why?
|
Toluidines | 2 | 2006 | 17 | 0.030 |
Why?
|
Hydroxybutyrates | 2 | 2006 | 27 | 0.030 |
Why?
|
Islets of Langerhans Transplantation | 1 | 1997 | 225 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 136 | 0.030 |
Why?
|
Aniline Compounds | 2 | 2006 | 55 | 0.030 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 154 | 0.030 |
Why?
|
Urine | 2 | 2006 | 90 | 0.030 |
Why?
|
Animals | 12 | 2005 | 26582 | 0.030 |
Why?
|
Age of Onset | 1 | 2016 | 310 | 0.030 |
Why?
|
Tumor Burden | 1 | 2016 | 289 | 0.030 |
Why?
|
Nitriles | 2 | 2006 | 149 | 0.030 |
Why?
|
DNA | 1 | 2001 | 1294 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2016 | 357 | 0.030 |
Why?
|
Papio | 3 | 2000 | 82 | 0.030 |
Why?
|
Ischemia | 1 | 1996 | 243 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 552 | 0.030 |
Why?
|
Mesons | 1 | 2014 | 9 | 0.030 |
Why?
|
Electrons | 1 | 2014 | 49 | 0.030 |
Why?
|
Jaundice | 1 | 2013 | 14 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2013 | 73 | 0.030 |
Why?
|
Autopsy | 1 | 2013 | 116 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2012 | 132 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2013 | 131 | 0.030 |
Why?
|
Syndecan-1 | 1 | 2012 | 13 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2012 | 220 | 0.030 |
Why?
|
Endothelial Protein C Receptor | 1 | 2012 | 4 | 0.030 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 44 | 0.030 |
Why?
|
Adiponectin | 1 | 2012 | 24 | 0.030 |
Why?
|
Acitretin | 1 | 2011 | 4 | 0.030 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 17 | 0.030 |
Why?
|
Yoga | 1 | 2011 | 5 | 0.030 |
Why?
|
Tetrahydronaphthalenes | 1 | 2011 | 15 | 0.030 |
Why?
|
Pseudolymphoma | 1 | 2011 | 9 | 0.030 |
Why?
|
Eczema | 1 | 2011 | 7 | 0.030 |
Why?
|
Captopril | 1 | 1991 | 20 | 0.030 |
Why?
|
Ultraviolet Therapy | 1 | 2011 | 15 | 0.030 |
Why?
|
Lymphocytes | 2 | 2008 | 464 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 64 | 0.030 |
Why?
|
Running | 1 | 2011 | 25 | 0.030 |
Why?
|
Silver Staining | 1 | 2011 | 6 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2011 | 64 | 0.020 |
Why?
|
Veins | 1 | 2011 | 94 | 0.020 |
Why?
|
Arm | 1 | 2011 | 91 | 0.020 |
Why?
|
Dendritic Cells, Follicular | 1 | 2010 | 20 | 0.020 |
Why?
|
Bacteremia | 1 | 2011 | 99 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 213 | 0.020 |
Why?
|
Germinal Center | 1 | 2010 | 55 | 0.020 |
Why?
|
Herpes Simplex | 1 | 2011 | 202 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 859 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2010 | 164 | 0.020 |
Why?
|
Skin Care | 1 | 2009 | 4 | 0.020 |
Why?
|
Ointments | 1 | 2009 | 12 | 0.020 |
Why?
|
Cosmetics | 1 | 2009 | 7 | 0.020 |
Why?
|
Liver Transplantation | 1 | 1997 | 1268 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2011 | 149 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 1996 | 1169 | 0.020 |
Why?
|
Porokeratosis | 1 | 2008 | 3 | 0.020 |
Why?
|
Betamethasone | 1 | 2008 | 5 | 0.020 |
Why?
|
Granulocytes | 1 | 2008 | 37 | 0.020 |
Why?
|
Radiography | 1 | 2011 | 813 | 0.020 |
Why?
|
Pruritus | 1 | 2008 | 26 | 0.020 |
Why?
|
Antibodies, Heterophile | 2 | 1999 | 20 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2010 | 272 | 0.020 |
Why?
|
Guanidines | 2 | 1999 | 31 | 0.020 |
Why?
|
Alopecia | 1 | 2008 | 34 | 0.020 |
Why?
|
Peroxidase | 2 | 1999 | 51 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2009 | 114 | 0.020 |
Why?
|
Epidermis | 1 | 2008 | 100 | 0.020 |
Why?
|
Ureter | 1 | 2009 | 92 | 0.020 |
Why?
|
Antibody Formation | 2 | 2000 | 171 | 0.020 |
Why?
|
Doxorubicin | 1 | 2009 | 295 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2008 | 233 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2012 | 724 | 0.020 |
Why?
|
Reoperation | 2 | 2002 | 597 | 0.020 |
Why?
|
Idarubicin | 1 | 2006 | 8 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2010 | 2062 | 0.020 |
Why?
|
Base Sequence | 1 | 2010 | 2330 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2007 | 278 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2008 | 1014 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2008 | 363 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 894 | 0.020 |
Why?
|
Blood | 1 | 2006 | 69 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 3030 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 339 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 1999 | 1219 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 1996 | 1721 | 0.020 |
Why?
|
Urinary Calculi | 1 | 2005 | 46 | 0.020 |
Why?
|
Diabetic Nephropathies | 1 | 2007 | 248 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 1997 | 456 | 0.020 |
Why?
|
Urothelium | 1 | 2005 | 70 | 0.020 |
Why?
|
Ileum | 1 | 2005 | 159 | 0.020 |
Why?
|
Virus Replication | 1 | 2006 | 319 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 1999 | 1376 | 0.010 |
Why?
|
Viral Load | 1 | 2003 | 148 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 1999 | 1195 | 0.010 |
Why?
|
Epithelioid Cells | 1 | 2000 | 13 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2006 | 2818 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 1036 | 0.010 |
Why?
|
Natriuresis | 1 | 1999 | 30 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2007 | 2501 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1999 | 172 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 376 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1999 | 231 | 0.010 |
Why?
|
Nevus, Intradermal | 1 | 1997 | 5 | 0.010 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 1997 | 74 | 0.010 |
Why?
|
Nephrosis, Lipoid | 1 | 1997 | 6 | 0.010 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 1997 | 19 | 0.010 |
Why?
|
Enalapril | 1 | 1997 | 18 | 0.010 |
Why?
|
Nevus | 1 | 1997 | 15 | 0.010 |
Why?
|
Abatacept | 1 | 1997 | 83 | 0.010 |
Why?
|
Hemoperfusion | 1 | 1997 | 5 | 0.010 |
Why?
|
CTLA-4 Antigen | 1 | 1997 | 135 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2003 | 567 | 0.010 |
Why?
|
Morbidity | 1 | 1997 | 148 | 0.010 |
Why?
|
Age Distribution | 1 | 1997 | 204 | 0.010 |
Why?
|
Haplorhini | 1 | 1997 | 81 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 1997 | 66 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1997 | 71 | 0.010 |
Why?
|
Cisplatin | 1 | 1999 | 612 | 0.010 |
Why?
|
Splenectomy | 1 | 1997 | 82 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1997 | 66 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1996 | 66 | 0.010 |
Why?
|
Whole-Body Irradiation | 1 | 1997 | 63 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 1997 | 154 | 0.010 |
Why?
|
Isoantibodies | 1 | 1997 | 114 | 0.010 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1997 | 190 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1997 | 154 | 0.010 |
Why?
|
Reperfusion | 1 | 1996 | 31 | 0.010 |
Why?
|
Hepacivirus | 1 | 1997 | 159 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1997 | 177 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 231 | 0.010 |
Why?
|
Cohort Studies | 1 | 2003 | 2767 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1997 | 557 | 0.010 |
Why?
|
Mice | 2 | 1999 | 11352 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1997 | 444 | 0.010 |
Why?
|
Administration, Oral | 1 | 1996 | 684 | 0.010 |
Why?
|
Gene Expression | 1 | 1999 | 1284 | 0.010 |
Why?
|
Dendritic Cells | 1 | 1998 | 425 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 1996 | 353 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 1997 | 728 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 1996 | 999 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1999 | 1981 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1996 | 1961 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1991 | 141 | 0.010 |
Why?
|
Pilot Projects | 1 | 1991 | 839 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 1999 | 2360 | 0.000 |
Why?
|